---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-006504"
form_type: "8-K"
ticker: "RNXT"
cik: "0001574094"
company_name: "RenovoRx, Inc."
filed_at: "2023-03-02T23:59:59+00:00"
generated_at: "2026-06-18T15:09:32.270032+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# RenovoRx reports FY2022 net loss $9.9M; Phase III pancreatic cancer trial interim analysis triggered

## Summary
- Net loss $9.9M for FY2022 vs $6.3M in 2021; diluted EPS ($1.09) vs ($1.21).
- Cash $6.4M as of Dec 31, 2022; expects to fund operations into Q3 2023.
- Phase III TIGeR-PaC trial: first interim analysis triggered after 26 events (30% of 86); DMC review underway; results expected within a week.
- 47 of 114 target patients randomized; second interim analysis expected in 2024.
- Operating expenses $10.0M, up from $5.7M; R&D $4.3M, G&A $5.6M.

## SEC filing metadata
- accession: 0001493152-23-006504
- form_type: 8-K
- ticker: RNXT
- cik: 0001574094
- company_name: RenovoRx, Inc.
- filed_at: 2023-03-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574094/000149315223006504/0001493152-23-006504-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574094/000149315223006504/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-006504
- JSON: https://secwatch.observer/filing/0001493152-23-006504.json
- Plain text: https://secwatch.observer/filing/0001493152-23-006504.txt

## Key facts
- Earnings Releases
  RenovoRx, Inc. reported year ended December 31, 2022 results: net income Net loss was $9.9 million for the ended December 31, 2022, EPS Net loss per share, basic and diluted were ($1.09) for the year ended December 31, 2022.
  - Period: year ended December 31, 2022
  - Net income: Net loss was $9.9 million for the ended December 31, 2022
  - EPS: Net loss per share, basic and diluted were ($1.09) for the year ended December 31, 2022
  - Result: reported results
  source text: ● Net loss was $9.9 million for the ended December 31, 2022, compared to net loss of $6.3 million for year ended December 31, 2021. ● Net loss per share, basic and diluted were ($1.09) for the year ended December 31, 2022, compared to ($1.21) for the year ended December 31, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1574094/000149315223006504/0001493152-23-006504-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.